V114 + Prevnar 13™ + PNEUMOVAX™23
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Pneumococcal Infections
Conditions
Pneumococcal Infections
Trial Timeline
Sep 12, 2018 → Nov 4, 2021
NCT ID
NCT03565900About V114 + Prevnar 13™ + PNEUMOVAX™23
V114 + Prevnar 13™ + PNEUMOVAX™23 is a phase 3 stage product being developed by Merck for Pneumococcal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT03565900. Target conditions include Pneumococcal Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03921424 | Phase 3 | Completed |
| NCT03565900 | Phase 3 | Completed |
| NCT03547167 | Phase 3 | Completed |
| NCT03480802 | Phase 3 | Completed |
| NCT03480763 | Phase 3 | Completed |
Competing Products
20 competing products in Pneumococcal Infections